Can-Fite BioPharma (CANF) Profit After Tax (QoQ) (2014 - 2023)
Can-Fite BioPharma (CANF) Profit After Tax (QoQ) (2014 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 6.24% |
| Sep 30, 2023 | 36.09% |
| Jun 30, 2023 | -1.66% |
| Mar 31, 2023 | -465.00% |
| Dec 31, 2022 | 81.02% |
| Sep 30, 2022 | -15.43% |
| Jun 30, 2022 | 9.98% |
| Mar 31, 2022 | 88.47% |
| Dec 31, 2021 | -720.94% |
| Sep 30, 2021 | -51.25% |
| Jun 30, 2021 | 471.41% |
| Mar 31, 2021 | 48.31% |
| Dec 31, 2020 | -41.09% |
| Sep 30, 2020 | 33.86% |
| Jun 30, 2020 | 10.34% |
| Mar 31, 2020 | 9.24% |
| Dec 31, 2019 | -62.28% |
| Sep 30, 2019 | 56.16% |
| Jun 30, 2019 | -467.09% |
| Mar 31, 2019 | 153.43% |